Exelixis, Inc.

Data released on two spectrum selective kinase inhibitors: XL647, XL999

Published in Food and Drug Law Weekly, November 5th, 2004

Exelixis, Inc., (EXEL) released data at the 16th annual meeting of the European Organization for the Research and Treatment of Cancer (EORTC) in Geneva, Switzerland for two of its receptor tyrosine kinase (RTK) inhibitors currently in clinical development.

These preclinical data reveal that both XL647 and XL999 have promise for the treatment of various forms of cancer through selective inhibition of RTKs.

Both compounds are spectrum selective kinase inhibitors that simultaneously target multiple kinases implicated in various forms of cancer. Both compounds are in phase I clinical trials.

"The data released at EORTC is preclinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2004-11-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry